๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease

โœ Scribed by L. Gustafson

Book ID
114784000
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
297 KB
Volume
88
Category
Article
ISSN
0001-6314

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

TETRAHYDROAMINOACRIDINE AND ALZHEIMER'S
TETRAHYDROAMINOACRIDINE AND ALZHEIMER'S DISEASE
โœ Katona, CorneliusL.E.; O'Brien, Catherine; Tyrrell, P.; Hardy, J.; Rossor, M.; W ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› The Lancet ๐ŸŒ English โš– 347 KB
Tetrahydroaminoacridine and lecithin in
Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease
โœ Henry C. Weinstein; Saskia Teunisse; Willem A. Gool ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer ๐ŸŒ English โš– 529 KB

In 12 ambulant patients with a clinical diagnosis of probable Alzheimer's disease, a 12-week, double-blind, placebo-controlled study with 100 mg/day tetrahydroaminoacridine (THA) and 10 g/day lecithin is reported. The aim of the study was to find whether treatment would result in an improvement of c

Tetrahydroaminoacridine in Alzheimer's d
Tetrahydroaminoacridine in Alzheimer's disease
โœ B. Davies; D. Andrewes; R. Stargatt; D. Ames; V. Tuckwell; S. Davis ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 445 KB ๐Ÿ‘ 1 views

Tetrahydroaminoacridine (THA), a centrally acting anticholinesterase, was used in a two-month, double-blind, placebo-controlled crossover trial to treat 10 patients meeting DSM-111-R criteria for dementia of the Alzheimer type. Eight patients continued to take THA for a further three months. Nausea